Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche’s blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response. However, as a humanized version of rituximab, it is hypothesized to induce less immunogenicity. Ocrevus is now wholly owned by Roche, with former development partner Biogen entitled to royalties of its sales in the US.
Although Ocrevus has been previously investigated in rheumatoid arthritis, it is now specifically for use in MS. Ocrevus was first approved in the US for the treatment of relapsing and PPMS in March 2017, and remains under regulatory review in other regions.
LIST OF FIGURES 8 Figure 32: Ocrevus for multiple sclerosis – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary for Ocrevus in multiple sclerosis
LIST OF TABLES 5 Table 1: Ocrevus drug profile
11 Table 48: Ponesimod Phase III trials in multiple sclerosis
12 Table 3: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.